

1. A method for treating an indication resulting from an alpha 6 subunit containing integrin-mediated pathological condition in a mammal, the method comprising administering to the mammal a treatment effective amount of an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent.

3. The method of claim 1, wherein the cell is contacted with an additional active ingredient along with said peptide, said active ingredient being selected from the group consisting of anti-leukotrienes, beta<sub>2</sub> antagonists and corticosteroids.

5. The method of claim 3, wherein said inflammation is mediated by a pro-inflammatory agent selected from the group consisting of cytokines, chemokines, chemotaxins and mitogens.

7. The method of claim 1, wherein said alpha 6 subunit containing integrin-mediated pathological condition is cell metastasis.

10.

1

11.  
containing i

claim 10  
signal t  
f-Met-L  
e-Phe a

subun

14. The cell surface complex of claim 13, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification

agent is a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

15. A method for modulating an alpha 6 subunit containing integrin-mediated response, said method comprising forming a complex of a cell surface  $\alpha_6$  integrin subunit and an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent.

16. The method of claim 15, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

17. A cell surface receptor complex comprising:  
 an  $\alpha_6$  integrin subunit and an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent,  
 wherein compared to cells not contacted by the candidate integrin-mediated signal transduction pathway modification agent there is a change in the amount of PI3, Raf, Ras, Src, Erk-1, PLC  $\gamma$ , G-protein  $\alpha$ , G-protein  $\beta$  or G-protein  $\gamma$  kinases.

18. A cell surface complex comprising the VLA-6 integrin receptor and an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent.

19. The cell surface complex of claim 18, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

09863637.052304  
 F06250 2599860

21. The method of claim 20, wherein said alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent is a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

23. A cell surface complex comprising the VLA-6 integrin receptor and an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent.

25. A method for modulating an integrin-mediated response, said method comprising forming a complex of the VLA-6 integrin receptor and an alpha 6 subunit containing integrin-mediated signal transduction pathway modification agent.

~~26. The me~~  
~~integrin-mediated sig~~  
~~having the formula f~~  
~~Tyr, Tyr-Phe, Phe-Phe~~

attaching an alpha 6 subunit to an affinity column;

recovering bound agent by eluting in the presence of excess alpha 6  
unit; and

identifying the eluted bound agent.